Active substanceAmoxicillin + Clavulanic acidAmoxicillin + Clavulanic acid
Similar drugsTo uncover
  • Amovicomb®
    powder in / in 
  • Amoxivan®
    powder in / in 
    ELFA NPC, CJSC     Russia
  • Amoxiclav®
    pills inwards 
    Lek dd     Slovenia
  • Amoxiclav®
    powder in / in 
    Lek dd     Slovenia
  • Amoxiclav®
    powder inwards 
    Lek dd     Slovenia
  • Amoxiclav® Quicactab
    pills inwards 
    Lek dd     Slovenia
  • Amoxiclav® Quicactab
    pills inwards 
    Sandoz d.     Slovenia
  • Pfizer Inc.     USA
  • VIAL, LLC     Russia
  • KRASFARMA, JSC     Russia
  • Arlet®
    pills inwards 
    POLLO, LLC     Russia
  • Augmentin®
    pills inwards 
  • Augmentin®
    powder in / in 
  • Augmentin®
    powder inwards 
  • Augmentin®
    pills inwards 
  • Augmentin®
    pills inwards 
  • Augmentin®
    powder inwards 
  • Augmentin® EC
    powder inwards 
  • Augmentin® SR
    pills inwards 
  • Bactoklave®
    powder inwards 
  • BetaClave®
    pills inwards 
  • Verklav
    powder in / in 
    RUSYUROFARM, LLC     Russia
  • Clamosar®
    powder in / in 
  • Medoklav
    powder in / in 
    Medocemi Co., Ltd.     Cyprus
  • Medoklav
    pills inwards 
    Medocemi Co., Ltd.     Cyprus
  • Medoflav®
    pills inwards 
    Medocemi Co., Ltd.     Cyprus
  • Medoklav
    powder inwards 
    Medocemi Co., Ltd.     Cyprus
  • Novaklav
    powder in / in 
    JODAS EKSPOIM, LLC     Russia
  • Panklaw 2X
    powder inwards 
    Hemofarm AD     Serbia
  • Panklaw 2X
    pills inwards 
    Hemofarm AD     Serbia
  • Ranclave®
    pills inwards 
  • Rapiklav®
    pills inwards 
  • Rapiklav®
    pills inwards 
  • Fibell
    powder in / in 
  • Fleymoclav Solutab®
    pills inwards 
    Astellas Farma Europe BV     Netherlands
  • Fleymoclav Solutab®
    pills inwards 
    Astellas Farma Europe BV     Netherlands
  • Foraclav
    powder in / in 
    FORTYUN MED, LTD     Russia
  • Ecoclave®
    powder inwards 
    STI-MED-SORB, OJSC     Russia
  • Ecoclave®
    pills inwards 
    AVVA RUS, OJSC     Russia
  • Dosage form: & nbsppowder for solution for intravenous administration
    Composition:

    1 bottle contains:

    Name of substance

    Contents in a vial (mg)

    Amoxicillin sodium in terms of amoxicillin

    1000

    Potassium clavulanate in terms of clavulanic acid

    200

    Description:

    Powder from white to almost white.

    Pharmacotherapeutic group:Antibiotic - penicillin semisynthetic + beta-lactamase inhibitor
    ATX: & nbsp

    J.01.C.R.02   Amoxicillin in combination with enzyme inhibitors

    Pharmacodynamics:

    Mechanism of action

    Amoxicillin is a semisynthetic broad-spectrum antibiotic with activity against many Gram-positive and Gram-negative microorganisms. In the same time amoxicillin is subject to destruction by beta-lactamases and therefore the spectrum of amoxicillin activity does not extend to microorganisms that produce these enzymes.

    Clavulanic acid, a beta-lactamase inhibitor structurally related to penicillins, has the ability to inactivate a wide spectrum of beta-lactamases found in microorganisms resistant to penicillins and cephalosporins. Clavulanic acid has sufficient efficacy against plasmid beta-lactamases,which most often determine the resistance of bacteria, and less effective against chromosomal beta-lactamase type 1.

    The presence of clavulanic acid in the preparation of Augmentin® protects amoxicillin from destruction by enzymes - beta-lactamases, which allows to expand the antibacterial spectrum of amoxicillin.

    The activity of a combination of amoxicillin with clavulanic acid in vitro.

    Bacteria, usually sensitive to a combination of amoxicillin and clavulanic acid

    Gram-positive aerobes

    Bacillus anthracis

    Enterococcus faecalis

    Gardnerella vaginalis

    Listeria monocytogenes

    Nocardia asteroides

    Streptococcus pneumoniae,1,2

    Streptococcus pyogenes1,2

    Streptococcus agalactiae1,2

    Group streptococci Viridans2

    Streptococcus spp. (others beta-hemolytic streptococci)12

    Staphylococcus aureus (sensitive to methicillin)1

    Staphylococcus saprophyticus (sensitive to methicillin)

    Coagulase-negative staphylococci (sensitive to methicillin)

    Gram-positive anaerobes

    Clostridium spp.

    Peptococcus niger

    Peptostreptococcus magnus

    Peptostreptococcus micros

    Peptostreptococcus spp.

    Gram-negative aerobes

    Bordetella pertussis

    Haemophilus influenzae1

    Helicobacter pylori

    Moraxella catarrhalis1

    Neisseria gonorrhoeae

    Pasteurella multocida

    Vibrio cholerae

    Gram-negative anaerobes

    Bacteroides fragilis

    Bacteroides spp.

    Capnocytophaga spp.

    Eikenella corrodens

    Fusobacterium nucleatum

    Fusobacterium spp.

    Porphyromonas spp.

    Prevotella spp.

    Other

    Borrelia burgdorferi

    Leptospira icterohaemorrhagiae

    Treponema pallidum

    Bacteria for which the acquired resistance to a combination of amoxicillin and clavulanic acid is probable

    Gram-negative aerobes

    Escherichia coli1

    Klebsiella oxytoca

    Klebsiella pneumoniae1

    Klebsiella spp.

    Proteus mirabilis

    Proteus vulgaris

    Proteus spp.

    Salmonella spp.

    Shigella spp.

    Gram-positive aerobes

    Corynebacterium spp.

    Enterococcus faecium

    Bacteria, possessing natural sustainability to combinations amoxicillin from clavulanate acid

    Gram-negative aerobes

    Acinetobacter spp.

    Citrobacter freundii

    Enterobacter spp.

    Hajhia alvei

    Legionella pneumophila

    Morganella morganii

    Providencia spp.

    Pseudomonas spp.

    Serratia spp.

    Stenotrophomonas maltophilia

    Yersinia enterocolitica

    Other

    Chlamydia pneumoniae

    Chlamydia psittaci

    Chlamydia spp.

    Coxiella burnetii

    Mycoplasma spp.

    1 - for these bacteria, the clinical efficacy of the combination of amoxicillin with clavulanic acid has been demonstrated in clinical studies.

    2 - strains of these bacteria do not produce beta-lactamases. Sensitivity to monotherapy with amoxicillin suggests a similar sensitivity to the combination of amoxicillin and clavulanic acid.

    Pharmacokinetics:

    Suction

    Below are the results of pharmacokinetics studies for intravenous bolus administration of healthy volunteers of the Augmentin drug at a dosage of 500 mg + 100 mg (0.6 g) or 1000 mg + 200 mg (1.2 g).

    Bolus intravenous injection

    Active substances in the drug Augmentin®

    Mean values ​​of pharmacokinetic parameters

    Dose

    (mg)

    FROMmOh

    (μg / ml)

    T1 / 2 (hours)

    AUC (h x mg / l)

    Excretion in urine,% 0-6 h

    Amoxicillin

    500

    32,2

    1,07

    25,5

    66,5

    1000

    105,4

    0,9

    76,3

    77,4

    Clavulanic acid

    100

    10,5

    1D2

    9,2

    46,0

    200

    28,5

    0,9

    27,9

    63,8

    FROMmah - the maximum concentration in the blood plasma.

    T1 / 2 - half-life.

    AUC - the area under the pharmacokinetic curve of the concentration-time relationship.

    Distribution

    When administered intravenously, the combination of amoxicillin with clavulanic acid, therapeutic concentrations of amoxicillin and clavulanic acid are found in various tissues and interstitial fluid (in the gall bladder, abdominal tissue, skin, fat and muscle tissues, synovial and peritoneal fluids, bile, purulent).

    Amoxicillin and clavulanic acid have a weak degree of binding to plasma proteins. Studies have shown that about 13-20% of each component of the Augmentin ® drug binds to plasma proteins.

    In animal studies, no cumulation of components of the Augmentin® preparation in any organ was detected.

    Amoxicillin, like most penicillins, penetrates into breast milk. Traces of clavulanic acid can also be detected in breast milk. Except for the possible development of diarrhea or candidiasis of the oral cavity mucous membranes, no known other negative effects of amoxicillin and clavulanic acid to the health of infants,breastfed. Studies of reproductive function in animals have shown that amoxicillin and clavulanic acid penetrate the placental barrier. However, there was no adverse effect on the fetus.

    Metabolism

    10-25% of the initial dose of amoxicillin is excreted by the kidneys in the form of an inactive metabolite (penicillic acid). Clavulanic acid undergoes intensive metabolism to 2,5-dihydro-4- (2-hydroxyethyl) -5-oxo-1 H-pyrrole-3-carboxylic acid and 1-amino-4-hydroxybutane-2h) on and is excreted by the kidneys, through the gastrointestinal tract (GIT), and also with exhaled air in the form of carbon dioxide.

    Excretion

    Like other penicillins, amoxicillin is excreted mainly by the kidneys, whereas clavulanic acid - by means of both renal and extrarenal mechanisms. Approximately 60-70% amoxicillin and 40-65% clavulanic acid are excreted by the kidneys unchanged in the first 6 hours after a single bolus injection of the Augmentin® preparation at a dosage of 500 mg + 100 mg or 1000 mg + 200 mg.

    The simultaneous administration of probenecid slows down the excretion of amoxicillin, but does not slow the renal excretion of clavulanic acid (see Fig.section "Interaction with other medicinal products").

    Indications:

    The combination of amoxicillin with clavulanic acid is indicated for the treatment of bacterial infections of the following localizations caused by microorganisms sensitive to a combination of amoxicillin and clavulanic acid:

    - Upper respiratory tract infections (including ENT diseases), for example, relapsing tonsillitis, sinusitis, otitis media, usually caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis# and Streptococcus pyogenes.

    - Infections of the lower respiratory tract, for example exacerbations of chronic bronchitis, lobar pneumonia and bronchopneumonia, usually caused Streptococcus pneumoniae, Haemophilus influenzae# and Moraxella catarrhalis#.

    - Urinary tract infections, for example, cystitis; urethritis, pyelonephritis, infections of female genital organs, usually caused by species of the family Enterobacteriaceae# (mainly Escherichia coif), Staphylococcus saprophyticus and species Enterococcus, as well as gonorrhea caused by Neisseria gonorrhoeal.

    - Infections of the skin and soft tissues, usually caused Staphylococcus aureus#, Streptococcus pyogenes and species Bacteroidef.

    - Infections of bones and joints, for example, osteomyelitis; usually called Staphylococcus aureus#, if necessary, long-term therapy is possible.

    - Other mixed infections (eg, septic abortion,postpartum sepsis, intra-abdominal sepsis, sepsis, peritonitis, postoperative infections) within the framework of stepwise therapy.

    - The drug Augmentin® at a dosage of 1000 mg + 200 mg also shows the day of prophylaxis of postoperative infections, with surgical interventions on the gastrointestinal tract, pelvic organs, head and neck, heart, kidneys, bile ducts, and implantation of artificial joints.

    # - Individual representatives of this kind of microorganisms produce beta-lactamase, which makes them insensitive to amoxicillin (see also the section "Pharmacological properties").

    Infections caused by microorganisms sensitive to amoxicillin can be treated with the Augmentin® drug, since amoxicillin is one of its active substances. Augmentin® is also indicated for the treatment of mixed infections caused by microorganisms that are sensitive to amoxicillin, as well as by microorganisms producing beta-lactamases that are sensitive to a combination of amoxicillin and clavulanic acid.

    The sensitivity of bacteria to the combination of amoxicillin and clavulanic acid varies depending on the region and over time.Wherever possible, local sensitivity data should be taken into account. If necessary, the collection of microbiological samples and analysis for bacteriological sensitivity should be carried out.

    Contraindications:

    - Hypersensitivity to amoxicillin, clavulanic acid, other components of the drug; beta-lactam antibiotics (eg, penicillins, cephalosporins) in the anamnesis;

    - previous episodes of jaundice or impaired liver function when using a combination of amoxicillin with clavulanic acid in the anamnesis.

    Carefully:

    The drug Augmentin ® should be used with caution in patients with impaired liver function and impaired renal function (creatinine clearance less than 30 ml / min).

    Pregnancy and lactation:

    Pregnancy

    In studies of reproductive function in animals, oral and parenteral administration of the Augmentin® drug did not produce teratogenic effects.

    In a single study in women with premature rupture of membranes, it was found that preventive therapy with the drug may be associated with increased risk of developing necrotizing enterocolitis in newborns.Like all medicines, Augmentin® is not recommended for use during pregnancy, unless the expected benefit to the mother exceeds the potential risk to the fetus.

    Lactation

    The drug Augmentin ® can be used during breastfeeding. With the exception of the possibility of developing diarrhea or candidiasis of the oral mucosa associated with the penetration of trace amounts of the active ingredients of this preparation into breast milk, no other adverse effects were observed in infants fed breastfeeding. In case of adverse effects in infants who are breastfeeding, it is necessary to stop it.

    Dosing and Administration:

    The dosage regimen is set individually depending on the age, body weight, function of the patient's kidneys, and also on the severity of the infection.

    Treatment should not last more than 14 days without reviewing the clinical situation. The drug Augmentin is not intended for intramuscular administration (due to instability at a concentration that could be administered intramuscularly).Doses are given in terms of the active ingredients: amoxicillin and clavulanic acid.

    Adults and children over 12 years of age or with a body weight of 40 kg or more

    Infections of mild to moderate severity: a dose of 1000 mg + 200 mg every 8 hours.

    Severe infections: a dose of 1000 mg + 200 mg every 4-6 hours.

    Prophylaxis in surgery

    Interventions lasting less than 1 h: a dose of 1000 mg + 200 mg during the initial anesthesia.

    Interventions lasting more than 1 hour: 1 dose of 1000 mg + 200 mg during anesthesia and then up to 4 doses of 1000 mg + 200 mg for 24 hours.

    Special patient groups

    Children

    For children weighing less than 40 kg, the dose is calculated depending on the body weight. In children younger than 3 months, the drug Augmentin ® should be administered only slowly infusion for 30-40 minutes.

    Less than 3 months with a body weight of less than 4 kg

    25 mg amoxicillin and 5 mg clavulanic acid per 1 kg body weight every 12 hours. Less than 3 months with a body weight of more than 4 kg

    25 mg of amoxicillin and 5 mg of clavulanic acid per 1 kg of body weight every 8 hours.

    From 3 months to 12 years with a body weight of less than 40 kg

    25 mg amoxicillin and 5 mg clavulanic acid per 1 kg body weight every 6-8 hours, depending on the severity of the infection.

    Elderly patients

    Dosage adjustment, dosing as in adult patients is not required. Patients with impaired renal function

    Correction of the dosing regimen is based on the maximum recommended dose of amoxicillin.

    Adults

    Creatinine clearance> 30 ml / min

    Correction of the dosing regimen is not required.

    Creatinine clearance 10-30 ml / min

    The initial dose of 1000 mg + 200 mg and further 500 mg + 100 mg 2 times a day.

    Creatinine clearance <10 ml / min

    The initial dose of 1000 mg + 200 mg and further 500 mg + 100 mg every 24 hours.

    Children

    Creatinine clearance> 30 ml / min

    Correction of the dosing regimen is not required.

    Creatinine clearance 10-30 ml / min

    25 mg + 5 mg per 1 kg 2 times a day.

    Creatinine clearance <10 ml / min

    25 mg + 5 mg per 1 kg every 24 hours.

    Patients, on hemodialysis

    Correction of the dosing regimen is based on the maximum recommended dose of amoxicillin.

    Adults

    Initially, 1 dose of 1000 mg + 200 mg, followed by 500 mg + 100 mg every 24 hours and an additional 500 mg + 100 mg at the end of the hemodialysis session (to compensate for the decrease in amoxicillin and clavulanic acid levels in the blood plasma).

    Children

    25 mg of amoxicillin and 5 mg of clavulanic acid per 1 kg of body weight every 24 hours and an additional 12.5 mg of amoxicillin and 2.5 mg of clavulanic acid per kg of body weight at the end of the hemodialysis session (to compensate for the decrease in amoxicillin and clavulanic acid levels in blood plasma ) and further 25 mg of amoxicillin and 5 mg of clavulanic acid per 1 kg of body weight per day.

    Patients with impaired hepatic function

    Treat with caution; regularly monitor liver function.

    There is insufficient data to change the recommendation for doses in such patients.

    Mode of application

    Bolus injection

    The drug Augmentin can be administered as a slow intravenous injection of 3-4 minutes duration directly into the vein or through a catheter.

    The contents of 1 bottle are diluted in 20 ml of water for injection, the total volume of the solution is 20.9 ml. During the preparation, the solution may acquire a pink color that disappears afterwards. The finished solution can have a color from colorless to light-straw.

    The resulting solution should be introduced within 20 minutes after dilution.

    Infusion introduction

    The drug Augmentin® is administered intravenously drip for 30-40 minutes.

    The solution prepared as described above for bolus administration without delay is added to 100 ml of one of the infusion solutions listed in the table below.

    Infusion solutions

    Stability period at 25 ° C (hours)

    Water for injections

    4

    A solution of sodium chloride 0.9%

    4

    Sodium lactate solution for intravenous administration

    4

    Ringer's solution

    3

    Ringer's lactate solution according to Hartman

    3

    The solution prepared at room temperature can be stored under the same conditions, and the infusion must be completed before the expiration of the period indicated in the table above. The solution can be stored at 5 ° C for 8 hours. To this end, the solution prepared as described above for bolus administration is added to a pre-chilled vial with 100 ml of infusion water or 100 ml of 0.9% sodium chloride solution.

    Solutions that were stored at a temperature of 5 ° C, must be entered immediately after they reach room temperature.

    The stability of the solution of the combination of amoxicillin with clavulanic acid depends on the concentration. If more concentrated solutions are needed, the stability time of the solution will change accordingly.

    Any remaining amounts of solution must be destroyed.

    Vials of the drug Augmentin® are not intended for repeated use.

    Side effects:

    The adverse events presented below are listed in accordance with the damage to organs and organ systems and frequency of occurrence.Frequency of occurrence is defined as follows: Often (1/10), often (1/100 and <1/10), infrequently ( 1/1 000 and <1/100), rarely ( 1/10 000 and <1/1 000), rarely (<1/10 000, including individual cases). Frequency categories were formed on the basis of clinical studies of the drug and post-registration surveillance.

    Frequency of occurrence of undesirable phenomena

    Infectious and parasitic diseases

    Often: candidiasis of skin and mucous membranes.

    Violations of the blood and lymphatic system

    Rarely: reversible leukopenia (including neutropenia), reversible thrombocytopenia.

    Rarely: reversible agranulocytosis and reversible hemolytic anemia, prolongation of bleeding time and prothrombin time; eosinophilia, thrombocytosis, anemia.

    Immune system disorders

    Rarely: angioedema, anaphylactic reactions, syndrome, similar to serum sickness, allergic vasculitis.

    Disturbances from the nervous system

    Infrequent: dizziness, headache.

    Rarely: convulsions. Seizures can be observed in patients with impaired renal function, as well as those who receive high doses of the drug. Insomnia, agitation, anxiety, behavior change.

    Vascular disorders

    Rarely: thrombophlebitis in the area of ​​injection.

    Disorders from the gastrointestinal tract

    Often: diarrhea.

    Infrequently: nausea, vomiting, dyspeptic disorders.

    Rarely: antibiotic-associated colitis (including pseudomembranous and hemorrhagic (see section "Special instructions and precautions"), is less common with the parenteral administration of the drug Augmentin.

    Disturbances from the liver and bile ducts

    Infrequent: moderate increase in activity of aspartate aminotransferase and / or alanine aminotransferase (ACT and / or ALT).

    This phenomenon is observed in patients receiving therapy with any antibiotic of the penicillin series, but its effect on the clinical condition of the patient is unknown.

    Rarely: hepatitis and cholestatic jaundice. These phenomena are observed in patients receiving penicillin antibiotics and cephalosporins. Increased activity of alkaline phosphatase, hyperbilirubinemia. Undesirable liver side effects were observed mainly in men and elderly patients and may be associated with long-term therapy.

    These signs and symptoms usually occur in the process or immediately after the end of therapy, but in some cases may not appear for several weeks after the completion of therapy. Undesirable phenomena are usually reversible. Undesirable phenomena from the liver can be severe, in extremely rare cases there have been reports of lethal outcomes. In almost all cases, these were patients with severe concomitant pathologies or patients who received potentially hepatotoxic drugs at the same time.

    Disturbances from the skin and subcutaneous tissues Infrequently: skin rash, itching, hives.

    Rarely: polyforma of erythema.

    Rarely: Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative dermatitis, acute generalized exanthematous pustulosis.

    In case of skin allergic reactions treatment with the drug Augmentin ® should be discontinued.

    Disorders from the kidneys and urinary tract

    Rarely: interstitial nephritis, crystalluria (see section "Overdose").

    Overdose:

    Symptoms

    Symptoms on the part of the gastrointestinal tract and violations of the water-electrolyte balance can be observed.

    Amoxicillin crystalluria is described, in some cases leading to the development of renal failure (see section "Special instructions and precautions for use").

    Seizures may occur in patients with impaired renal function or in patients receiving high doses of the drug

    After intravenous administration of large doses of amoxicillin, it can precipitate in urinary catheters. Therefore, a regular check of the permeability of urinary catheters should be carried out.

    Treatment

    Symptoms from the gastrointestinal tract are symptomatic therapy, paying special attention to the normalization of the water-electrolyte balance. Amoxicillin and clavulanic acid can be removed from the bloodstream by hemodialysis.

    Interaction:

    Simultaneous use of the drug Augmentin® and probenecid is not recommended. Probenecid reduces the tubular secretion of amoxicillin, and therefore simultaneous use of the drug Augmentin and probenecid can lead to an increase and persistence in the blood concentration of amoxicillin, but not clavulanic acid.

    The simultaneous use of allopurinol and amoxicillin may increase the risk of skin allergic reactions.Currently, there is no data in the literature on the simultaneous use of a combination of amoxicillin with clavulanic acid and allopurinol.

    Penicillins can slow the excretion of methotrexate from the body by inhibiting its tubular secretion, so the simultaneous use of the drug Augmentin and methotrexate may increase the toxicity of methotrexate.

    Like other antibacterial drugs, the drug Augmentin can affect the intestinal microflora, leading to a decrease in absorption of estrogens from the digestive tract and a decrease in the effectiveness of combined oral contraceptives.

    The presence of clavulanic acid in the Augmentin® preparation may result in non-specific binding of the immunoglobulin G and albumin with a cell membrane of erythrocytes, which can lead to a false positive reaction with a Coombs sample.

    In the literature, rare cases of an increase in the international normalized ratio (INR) in patients with joint use of acenocoumarol or warfarin and amoxicillin are described. If it is necessary to simultaneously prescribe the Augmentin® drug with anticoagulants, prothrombin time or INR should be carefully monitored when the Augmentin® is prescribed or discontinued,it may be necessary to adjust the dose of anticoagulants for oral administration.

    In patients receiving mycophenolate mofetil, when the use of amoxicillin and clavulanic acid was started, a decrease in the concentration of the active metabolite-mycophenolic acid-was observed before taking the next dose of the drug by approximately 50%. Changes in concentration observed before the administration of the drug can not accurately reflect the overall changes in the concentration of mycophenolic acid.

    Pharmaceutical incompatibility

    The drug Augmentin should not be mixed with blood products, other protein-containing fluids, such as protein hydrolysates, or with intravenous lipid emulsions. When used simultaneously with aminoglycosides, antibiotics should not be mixed in a single syringe or in one vial for intravenous fluids, because aminoglycosides lose activity in such conditions.

    The drug solution of Augmentin® should not be mixed with solutions containing dextrose, dextran or sodium hydrogen carbonate.

    Special instructions:

    Before starting treatment with Augmentin, you need to collect a detailed medical history,concerning previous hypersensitivity reactions to penicillins, cephalosporins or other substances that cause an allergic reaction in the patient. Serious and sometimes lethal hypersensitivity reactions (anaphylactic reactions) to penicillins are described. The risk of occurrence of such reactions is highest in patients who have a history of hypersensitivity reactions to penicillins. In case of an allergic reaction, it is necessary to stop treatment with the drug Augmentin® and begin the appropriate alternative therapy. Serious anaphylactic reactions should be promptly administered to the patient epinephrine. Oxygen therapy, intravenous glucocorticosteroids, and airway patency, including intubation, may also be required.

    In case of suspected infectious mononucleosis, the drug Augmentin® should not be used, since in patients with this disease amoxicillin can cause a skinlike skin rash, which makes it difficult to diagnose the disease.

    Long-term treatment with the drug Augmentin® can lead to excessive reproduction of insensitive microorganisms.

    There are cases of pseudomembranous colitis occurring when taking antibiotics, the severity of which can range from mild to life-threatening. Thus, it is important to diagnose it in patients who develop diarrhea during or after the administration of antibiotics. If diarrhea is prolonged or the patient experiences abdominal cramps, treatment should be stopped immediately and the patient should be examined.

    In general, the drug Augmentin® is well tolerated and has a characteristic of all penicillins of low toxicity. During prolonged therapy with the drug Augmentin, it is recommended to periodically evaluate the function of the kidneys, liver and hematopoiesis.

    In patients who received a combination of amoxicillin with clavulanic acid in conjunction with indirect (oral) anticoagulants, in rare cases, increased prothrombin time (increased INR) was reported. With the joint appointment of indirect (plural) anticoagulants with a combination of amoxicillin and clavulanic acid, monitoring of the relevant indicators is necessary. To maintain the necessary effect of oral anticoagulants, it may be necessary to correct their dose-

    In patients with impaired renal function, the dose of Augmentin® should be reduced depending on the creatinine clearance (see the section "Dosing and Administration").

    The presence of clavulanic acid in the Augmentin® preparation may result in non-specific binding of the immunoglobulin G and albumin with a cell membrane of erythrocytes, which can lead to a false positive reaction with a Coombs sample. If parenteral administration of high doses of Augmentin is necessary, patients on a diet with a low salt content should take into account the presence of sodium ion in the preparation.

    In patients with reduced diuresis, crystalluria is very rare, mainly with parenteral therapy with the drug Augmentin. During the administration of large doses of amoxicillin, it is recommended to take a sufficient amount of fluid and maintain an adequate diuresis to reduce the likelihood of amoxicillin crystals (see "Overdose" section).

    Taking the Augmentin drug inside leads to a high content of amoxicillin in the urine, which can cause false positive results in the determination of glucose in the urine (for example, the Benedict test, Feeling's test).In this case, it is recommended to use a glucose oxidant method for determining the concentration of glucose in the urine.

    Abuse and drug dependence

    There was no drug dependence, addiction and reactions of euphoria associated with the use of the drug Augmentin.

    Effect on the ability to drive transp. cf. and fur:

    Since the drug may cause dizziness, it is necessary to warn patients about precautions when driving a vehicle or working with moving machinery.

    Form release / dosage:

    Powder for the preparation of a solution for intravenous administration, 1000 mg + 200 mg.

    Packaging:

    1000 mg + 200 mg in a transparent bottle with a capacity of 25 ml of glass type I or III (Hept. F.), sealed with chlorobutyl rubber stopper and aluminum cap or aluminum cap and snap-on lid.

    For 10 vials along with instructions for medical use are placed in a cardboard box.
    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date stated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N015030 / 03
    Date of registration:13.10.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:GlaxoSmithKline Trading, ZAO GlaxoSmithKline Trading, ZAO Russia
    Manufacturer: & nbsp
    Representation: & nbspGlaxoSmithKline group of companies GlaxoSmithKline group of companies Unknown
    Information update date: & nbsp04.10.2017
    Illustrated instructions
      Instructions
      Up